FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/17/2026
Back to search
Official data from USPTO
ALLO CHASSIS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ALLO CHASSIS
ST13
US500000079425095Class
1, 5, 40, 42
Filing
79425095
Registration
8172902
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
06/18/2026
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
04/07/2025
Registration date
03/17/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/17/2026
Last transaction
06/18/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
33
Owner location
BE
Examiner
EISNACH, MICHAEL PATRICK
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Celyntra Therapeutics SA
Representatives
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Modified cellsin particular genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefromfor research or scientific purposes; cell culturescell culture systems and cryopreserved genetically modified iPS cells for scientific and industrial research purposes; cell culturescryopreserved cells iPS cells other than for medical or veterinary use; Biological preparations for use in cell culturesother than for medical or veterinary purposescell culture agents for use in the biotechnology industry and cell material for use in combination with human cellsparticularly genetically modified iPS or differentiated stem cells
Class 5
Modified cellsin particular genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefromfor medical or veterinary use; cell cultures and cell culture systemscryopreserved pluripotent stem cells for medical or veterinary use; genetically modified iPS (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systemscryopreserved genetically modified pluripotent stem cells for sub cultivation of cells.
Class 40
Custom manufacturing of iPS derived cellsiPS derived cell therapy and manufacturing processes for othersmanufacturing of the foregoing cells in GMP-based facilities; custom manufacture of therapeutic cellsmedicinescell therapies and gene edited cell therapies for othersmanufacturing in GMP-based facilities; custom manufacture of cellular therapiesmanufacturing in GMP-based facilities; manufacturing of cell lines being modified cells with specific genetic edits for use in generating other cells
Class 42
Research and testing of cell-based productsin particular therapeutic products; researchoptimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefrom; Scientific researchdesign and development of scientific cell culturecell therapy and gene edited cell therapy; Scientific researchdesign and development of cell culturecell therapy or gene edited cell therapymanufacturing systems and manufacturing processes for others; platform as a service (PAAS) services featuring computer software platforms for custom manufacturing of cell-based productsin the field of cell therapycell therapy development; providing temporary use of online non-downloadable computer software platform for the management of manufacturing of cell-based therapiesthe associated technologyprocessesdata analytics capabilities for process optimization and quality control
Publications
History of USPTO decisions and trademark events.
19 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/17/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/17/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/27/2026
PUBO
PUBLISHED FOR OPPOSITION
01/27/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/21/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/05/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/30/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/30/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/30/2025
RFNT
REFUSAL PROCESSED BY IB
11/22/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/05/2025
RFRR
REFUSAL PROCESSED BY MPU
11/05/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/17/2025
CNRT
NON-FINAL ACTION WRITTEN
09/16/2025
DOCK
ASSIGNED TO EXAMINER
09/03/2025
MAFR
APPLICATION FILING RECEIPT MAILED
06/06/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/06/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/05/2025
Continuous trademark protection
Get notified about every new filing that threatens ALLO CHASSIS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.